...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products:(Date:10/7/2008)... EAU CLAIRE, Wis., Oct. 7 /PRNewswire/ -- Van Wer...latest facility to go live with LOGICARE(R),Corp.,...d(TM) EDIS., Van Wert County Hospital joins Conwa...outhern New Hampshire Medical Center, Nashua, New ...ir Emergency Departments., Van Wert County Hospit...
(Date:10/7/2008)... Wyndstorm Corporation ( ww...ues social media company, announced a key win with...ractive marketing plan program design to promote M...yndstorm,s design project will ultimately help Muv...rograms among employees via interactive messaging,...
(Date:10/7/2008)... http://www.boomj.com Featuring Daily Articles ...omen and Charities, HENDERSON, Nev., Oct. 7 /PRNe...rd: BOMJ) http://www.BOOMj.com, the leading soci...s over the age of 35 today announced,its commitmen...., (Logo: http://www.newscom.com/cgi-bin/prnh/20...
(Date:10/7/2008)... CLEVELAND, Oct. 7 /PRNewswire/ -- Cleveland Medi...awarded $1.23 million in NIH SBIR,FastTrack fundin...ParkinTune(TM), a system to augment stimulator pro...s for Parkinson,s disease (PD). CleveMed is,collab...ical Restoration of,the Cleveland Clinic Foundatio...
Breaking Medicine News(10 mins):Health News:Latest LOGICARE(R) EDIS User Sees 'Tremendous Results' 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3Health News:BOOMj, Inc. Joins Fight Against Breast Cancer 2Health News:BOOMj, Inc. Joins Fight Against Breast Cancer 3Health News:CleveMed Receives $1.23 Million in NIH Funding to Develop a System to Augment Deep Brain Stimulation Programming in Parkinson's Disease 2(Date:10/7/2008)...re-FirstCall/ - Burcon NutraScience,Corporation (T...,Supertein(TM) canola protein isolates are GRAS (G...e in a variety of food and beverage,applications. ...an,independent evaluation by a panel of qualified ...nutritional sciences, food allergies and pediatric...
(Date:10/7/2008)...wire-FirstCall/ -- CEL-SCI Corporation,(NYSE: CVM...rial Transfer,Agreement (MTA) with the National In... laboratory of Dr. Francesco M. Marincola, M.D., t...e tumor microenvironment,caused by CEL-SCI,s cance...e Infectious Disease and Immunogentics Section, De...
(Date:10/7/2008)... /- A study published in the,scientif...lf-renewal,reported that InVitria,s ( http://www....albumin) was an effective replacement to bovine se...tled, "The ground state of embryonic stem cell,sel...tim as a recombinant,albumin in place of animal-de...
(Date:10/7/2008)...RNewswire/ -- Taligen Therapeutics Inc.,today anno...s pipeline,candidates were presented at the XXII I...land. The data highlighted the candidates, efficac...diseases., "These highlighted presentations, as w...onference, reveal the deep expertise and expanding...
Breaking Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity 1443 1NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity 1443 2Home Care Agencies Responding to Patients Needs Still Have Room for Improvement 1441 1Home Care Agencies Responding to Patients Needs Still Have Room for Improvement 1441 2First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 1First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 2First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 3First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 4First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 5First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 6First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 7First Osteoporosis Study in Hip Fracture Patients Finds Once Yearly Reclast 28R 29 Prevents Additional Fractures and Improves Survival 288 8Directors Forum 3A PEPFAR and the Global AIDS Response 286 1Directors Forum 3A PEPFAR and the Global AIDS Response 286 2...om placebo,controlled phase IIa study in patients ...N (Zurich), Switzerland, May 15, 2007 - Cytos Biot...sults from a multi-centre,and placebo-controlled p...03-QbG10, an immunotherapeutic product candidate f...ncluded 40 patients,suffering from mild to moderat...
...07 - Synthetic Blood,International, Inc. (OTCBB:SY...al analysis of its Phase IIa study with Oxycyte(TM... with preliminary,study results announced in Decem...rimary endpoint of increasing patients, oxygen,ten...lso show a,decrease in patient glucose and lactate...
Other Medicine Technology:Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 2Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 4Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 5Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 6Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 7Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3